Gresham Richter
Concepts (598)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Vascular Malformations | 25 | 2025 | 105 | 7.950 |
Why?
| | Arteriovenous Malformations | 19 | 2024 | 74 | 7.630 |
Why?
| | Hemangioma | 15 | 2022 | 85 | 5.420 |
Why?
| | Glottis | 9 | 2024 | 34 | 3.800 |
Why?
| | Laryngomalacia | 10 | 2024 | 25 | 3.700 |
Why?
| | Propranolol | 10 | 2020 | 78 | 3.030 |
Why?
| | Lymphatic Abnormalities | 7 | 2020 | 20 | 3.000 |
Why?
| | Infant | 54 | 2024 | 3715 | 2.390 |
Why?
| | Neck | 12 | 2022 | 98 | 2.160 |
Why?
| | Child | 60 | 2025 | 7220 | 2.060 |
Why?
| | Sclerotherapy | 12 | 2023 | 47 | 1.880 |
Why?
| | Child, Preschool | 47 | 2024 | 4058 | 1.870 |
Why?
| | Humans | 133 | 2025 | 52539 | 1.810 |
Why?
| | Lasers, Solid-State | 5 | 2020 | 31 | 1.810 |
Why?
| | Laryngoscopy | 10 | 2020 | 59 | 1.710 |
Why?
| | Ambulatory Surgical Procedures | 3 | 2024 | 52 | 1.700 |
Why?
| | Laryngostenosis | 4 | 2020 | 12 | 1.690 |
Why?
| | Deglutition Disorders | 5 | 2017 | 79 | 1.680 |
Why?
| | Treatment Outcome | 38 | 2024 | 5484 | 1.610 |
Why?
| | Laser Therapy | 6 | 2020 | 76 | 1.510 |
Why?
| | Laryngoplasty | 2 | 2024 | 8 | 1.490 |
Why?
| | Vascular Surgical Procedures | 5 | 2020 | 166 | 1.380 |
Why?
| | Embolization, Therapeutic | 8 | 2023 | 90 | 1.330 |
Why?
| | Otolaryngology | 6 | 2025 | 61 | 1.330 |
Why?
| | Male | 79 | 2024 | 26831 | 1.320 |
Why?
| | Female | 77 | 2024 | 28236 | 1.230 |
Why?
| | Larynx | 7 | 2017 | 30 | 1.230 |
Why?
| | Tonsillectomy | 4 | 2021 | 49 | 1.230 |
Why?
| | Veins | 6 | 2023 | 74 | 1.220 |
Why?
| | Hemangioma, Capillary | 2 | 2020 | 12 | 1.190 |
Why?
| | Retrospective Studies | 35 | 2024 | 6662 | 1.170 |
Why?
| | Head | 6 | 2022 | 71 | 1.120 |
Why?
| | Skin | 7 | 2020 | 420 | 1.010 |
Why?
| | Trachea | 5 | 2018 | 54 | 0.900 |
Why?
| | Heart Bypass, Right | 1 | 2024 | 14 | 0.890 |
Why?
| | Head and Neck Neoplasms | 6 | 2015 | 288 | 0.890 |
Why?
| | Arteriovenous Fistula | 1 | 2024 | 27 | 0.880 |
Why?
| | Blood Proteins | 1 | 2024 | 84 | 0.860 |
Why?
| | Pulmonary Veins | 1 | 2024 | 42 | 0.860 |
Why?
| | Adolescent | 31 | 2024 | 6727 | 0.850 |
Why?
| | Facial Neoplasms | 2 | 2017 | 22 | 0.850 |
Why?
| | Tongue | 4 | 2023 | 40 | 0.840 |
Why?
| | Fontan Procedure | 1 | 2024 | 68 | 0.840 |
Why?
| | Vocal Cord Paralysis | 2 | 2022 | 23 | 0.840 |
Why?
| | Pulmonary Artery | 2 | 2024 | 147 | 0.830 |
Why?
| | Collagen | 4 | 2019 | 215 | 0.830 |
Why?
| | Surgery, Computer-Assisted | 3 | 2020 | 54 | 0.830 |
Why?
| | Otorhinolaryngologic Diseases | 2 | 2014 | 11 | 0.830 |
Why?
| | Cell Proliferation | 7 | 2023 | 1027 | 0.810 |
Why?
| | Proteome | 1 | 2024 | 170 | 0.790 |
Why?
| | Infant, Newborn | 20 | 2024 | 2884 | 0.790 |
Why?
| | Face | 2 | 2020 | 55 | 0.780 |
Why?
| | Health Information Systems | 1 | 2022 | 18 | 0.770 |
Why?
| | Respiratory Aspiration | 2 | 2014 | 8 | 0.760 |
Why?
| | Nitric Oxide Synthase Type III | 3 | 2013 | 83 | 0.760 |
Why?
| | Adrenergic beta-Antagonists | 4 | 2020 | 112 | 0.750 |
Why?
| | Hyperpigmentation | 1 | 2021 | 10 | 0.740 |
Why?
| | Proteomics | 1 | 2024 | 327 | 0.730 |
Why?
| | Cricoid Cartilage | 2 | 2020 | 11 | 0.730 |
Why?
| | Receptors, Progesterone | 1 | 2021 | 66 | 0.690 |
Why?
| | Otorhinolaryngologic Surgical Procedures | 3 | 2014 | 34 | 0.690 |
Why?
| | Graft Survival | 4 | 2011 | 161 | 0.680 |
Why?
| | Ambulatory Care Facilities | 1 | 2021 | 124 | 0.680 |
Why?
| | Intracranial Arteriovenous Malformations | 2 | 2019 | 32 | 0.680 |
Why?
| | Dermatologic Surgical Procedures | 1 | 2020 | 35 | 0.670 |
Why?
| | Receptors, Estrogen | 1 | 2021 | 132 | 0.670 |
Why?
| | Dilatation | 2 | 2017 | 27 | 0.670 |
Why?
| | Prospective Studies | 9 | 2022 | 2453 | 0.660 |
Why?
| | Risk Assessment | 10 | 2018 | 1348 | 0.650 |
Why?
| | Tracheostomy | 3 | 2022 | 76 | 0.640 |
Why?
| | Vasodilator Agents | 2 | 2017 | 93 | 0.620 |
Why?
| | Elastin | 1 | 2019 | 23 | 0.620 |
Why?
| | Inpatients | 1 | 2021 | 209 | 0.620 |
Why?
| | Gastroesophageal Reflux | 2 | 2017 | 48 | 0.610 |
Why?
| | Estradiol | 3 | 2018 | 217 | 0.610 |
Why?
| | Follow-Up Studies | 15 | 2018 | 2293 | 0.610 |
Why?
| | Skin Transplantation | 3 | 2009 | 44 | 0.610 |
Why?
| | Gene Expression Profiling | 3 | 2020 | 1108 | 0.610 |
Why?
| | Vascular Endothelial Growth Factor A | 3 | 2009 | 187 | 0.600 |
Why?
| | Thyroid Cartilage | 1 | 2018 | 2 | 0.590 |
Why?
| | Pharynx | 3 | 2014 | 31 | 0.590 |
Why?
| | Endothelial Cells | 4 | 2024 | 283 | 0.590 |
Why?
| | Vascular Neoplasms | 1 | 2018 | 17 | 0.590 |
Why?
| | Mast Cells | 1 | 2018 | 55 | 0.580 |
Why?
| | Postoperative Complications | 5 | 2024 | 1081 | 0.580 |
Why?
| | Endoscopy | 6 | 2015 | 123 | 0.580 |
Why?
| | Endovascular Procedures | 1 | 2020 | 179 | 0.560 |
Why?
| | Ki-67 Antigen | 3 | 2013 | 58 | 0.560 |
Why?
| | Young Adult | 13 | 2024 | 4326 | 0.560 |
Why?
| | Disease Models, Animal | 2 | 2013 | 1481 | 0.550 |
Why?
| | Gene Regulatory Networks | 1 | 2018 | 111 | 0.550 |
Why?
| | Deglutition | 3 | 2014 | 44 | 0.550 |
Why?
| | Respiratory Tract Infections | 2 | 2020 | 82 | 0.550 |
Why?
| | Adult | 32 | 2024 | 14160 | 0.540 |
Why?
| | Rectum | 1 | 2017 | 55 | 0.530 |
Why?
| | Vagina | 1 | 2017 | 46 | 0.530 |
Why?
| | Eosinophilic Esophagitis | 1 | 2017 | 43 | 0.530 |
Why?
| | Receptors, Adrenergic, beta | 1 | 2017 | 44 | 0.530 |
Why?
| | Renin-Angiotensin System | 1 | 2017 | 58 | 0.520 |
Why?
| | Laryngeal Neoplasms | 2 | 2015 | 44 | 0.520 |
Why?
| | Wound Healing | 4 | 2014 | 221 | 0.520 |
Why?
| | Ultrasonography, Prenatal | 1 | 2018 | 190 | 0.520 |
Why?
| | Bleomycin | 3 | 2022 | 38 | 0.510 |
Why?
| | Cerebral Palsy | 2 | 2014 | 38 | 0.500 |
Why?
| | Nasopharynx | 2 | 2020 | 34 | 0.500 |
Why?
| | Matrix Metalloproteinase 2 | 1 | 2016 | 58 | 0.500 |
Why?
| | Skin Neoplasms | 2 | 2022 | 500 | 0.490 |
Why?
| | Matrix Metalloproteinase 9 | 1 | 2016 | 87 | 0.490 |
Why?
| | Sleep Apnea, Obstructive | 2 | 2014 | 70 | 0.480 |
Why?
| | Hearing Aids | 5 | 2017 | 70 | 0.470 |
Why?
| | Blood Coagulation Disorders | 3 | 2020 | 38 | 0.460 |
Why?
| | Blotting, Western | 4 | 2021 | 593 | 0.460 |
Why?
| | Skin Ulcer | 1 | 2014 | 9 | 0.450 |
Why?
| | Alginates | 1 | 2014 | 12 | 0.450 |
Why?
| | Polysaccharides | 1 | 2014 | 54 | 0.440 |
Why?
| | Silver | 1 | 2014 | 47 | 0.430 |
Why?
| | Adenoidectomy | 2 | 2020 | 35 | 0.430 |
Why?
| | Organophosphonates | 1 | 2013 | 7 | 0.420 |
Why?
| | Periodicals as Topic | 1 | 2014 | 61 | 0.420 |
Why?
| | Cytosine | 1 | 2013 | 30 | 0.420 |
Why?
| | Sclerosing Solutions | 3 | 2022 | 16 | 0.410 |
Why?
| | Signal Transduction | 3 | 2020 | 1707 | 0.410 |
Why?
| | RNA, Messenger | 4 | 2022 | 1139 | 0.410 |
Why?
| | Nervous System Diseases | 1 | 2014 | 94 | 0.410 |
Why?
| | Palate | 1 | 2013 | 13 | 0.400 |
Why?
| | Uvula | 1 | 2013 | 13 | 0.400 |
Why?
| | Pharyngeal Diseases | 1 | 2013 | 12 | 0.400 |
Why?
| | Gestational Age | 3 | 2013 | 418 | 0.400 |
Why?
| | Choristoma | 1 | 2013 | 23 | 0.400 |
Why?
| | Infant, Premature, Diseases | 1 | 2013 | 97 | 0.390 |
Why?
| | Consensus | 5 | 2024 | 191 | 0.390 |
Why?
| | Thymus Gland | 1 | 2013 | 41 | 0.390 |
Why?
| | Surgical Flaps | 2 | 2020 | 110 | 0.390 |
Why?
| | Receptors, Cell Surface | 1 | 2013 | 112 | 0.380 |
Why?
| | Quality of Life | 3 | 2014 | 881 | 0.380 |
Why?
| | Comorbidity | 4 | 2024 | 631 | 0.380 |
Why?
| | Milk Hypersensitivity | 1 | 2012 | 19 | 0.380 |
Why?
| | Down Syndrome | 1 | 2013 | 93 | 0.380 |
Why?
| | Pilot Projects | 4 | 2019 | 719 | 0.380 |
Why?
| | Lymphangioma, Cystic | 1 | 2011 | 10 | 0.370 |
Why?
| | Endothelium, Lymphatic | 1 | 2011 | 8 | 0.370 |
Why?
| | Antigens, CD | 1 | 2013 | 215 | 0.370 |
Why?
| | Clinical Competence | 3 | 2020 | 400 | 0.370 |
Why?
| | Delphi Technique | 5 | 2024 | 64 | 0.370 |
Why?
| | Laryngeal Diseases | 2 | 2010 | 12 | 0.360 |
Why?
| | Milk Proteins | 1 | 2012 | 77 | 0.360 |
Why?
| | Mouth | 2 | 2010 | 33 | 0.360 |
Why?
| | Microtubule-Associated Proteins | 1 | 2011 | 64 | 0.360 |
Why?
| | Papillomavirus Infections | 1 | 2013 | 172 | 0.360 |
Why?
| | Homeodomain Proteins | 1 | 2011 | 81 | 0.350 |
Why?
| | Tracheoesophageal Fistula | 2 | 2008 | 11 | 0.350 |
Why?
| | Laryngeal Mucosa | 1 | 2011 | 4 | 0.350 |
Why?
| | Combined Modality Therapy | 7 | 2018 | 638 | 0.350 |
Why?
| | Laryngeal Nerves | 1 | 2011 | 15 | 0.350 |
Why?
| | Nervous System Physiological Phenomena | 1 | 2010 | 9 | 0.350 |
Why?
| | Magnetic Resonance Angiography | 3 | 2018 | 67 | 0.350 |
Why?
| | Tumor Suppressor Proteins | 1 | 2011 | 128 | 0.350 |
Why?
| | Osseointegration | 3 | 2017 | 25 | 0.340 |
Why?
| | Severity of Illness Index | 6 | 2014 | 1037 | 0.340 |
Why?
| | Neuromuscular Diseases | 1 | 2011 | 31 | 0.340 |
Why?
| | Hospitals, Special | 1 | 2010 | 9 | 0.330 |
Why?
| | Airway Obstruction | 3 | 2018 | 49 | 0.330 |
Why?
| | Cholesteatoma, Middle Ear | 2 | 2009 | 32 | 0.330 |
Why?
| | Capillaries | 2 | 2022 | 49 | 0.330 |
Why?
| | Cheek | 1 | 2010 | 9 | 0.330 |
Why?
| | Lip | 1 | 2010 | 11 | 0.330 |
Why?
| | Tracheal Neoplasms | 1 | 2009 | 8 | 0.320 |
Why?
| | Fibrin Tissue Adhesive | 2 | 2008 | 13 | 0.320 |
Why?
| | Immunohistochemistry | 4 | 2015 | 981 | 0.320 |
Why?
| | Multiple Endocrine Neoplasia Type 2a | 1 | 2009 | 5 | 0.320 |
Why?
| | Cicatrix | 2 | 2020 | 42 | 0.310 |
Why?
| | Carcinoma, Medullary | 1 | 2009 | 12 | 0.310 |
Why?
| | Tomography, X-Ray Computed | 7 | 2015 | 1164 | 0.310 |
Why?
| | Proteus mirabilis | 1 | 2009 | 2 | 0.310 |
Why?
| | Proteus Infections | 1 | 2009 | 4 | 0.310 |
Why?
| | Bacteroidaceae Infections | 1 | 2009 | 4 | 0.310 |
Why?
| | Electrocoagulation | 2 | 2009 | 12 | 0.310 |
Why?
| | Bacteroides | 1 | 2009 | 14 | 0.310 |
Why?
| | Brain Abscess | 1 | 2009 | 10 | 0.310 |
Why?
| | Otitis Media, Suppurative | 1 | 2009 | 7 | 0.310 |
Why?
| | Cerebellar Diseases | 1 | 2009 | 17 | 0.310 |
Why?
| | Proto-Oncogene Proteins c-ret | 1 | 2009 | 33 | 0.300 |
Why?
| | Vomiting | 2 | 2021 | 73 | 0.300 |
Why?
| | Quality Improvement | 2 | 2021 | 224 | 0.300 |
Why?
| | Injections, Intralesional | 3 | 2021 | 32 | 0.300 |
Why?
| | Child Development | 1 | 2010 | 201 | 0.300 |
Why?
| | Real-Time Polymerase Chain Reaction | 2 | 2021 | 186 | 0.300 |
Why?
| | Time Factors | 7 | 2020 | 2997 | 0.290 |
Why?
| | Risk Factors | 9 | 2020 | 3953 | 0.290 |
Why?
| | Electrosurgery | 1 | 2008 | 9 | 0.290 |
Why?
| | Tracheotomy | 2 | 2019 | 15 | 0.280 |
Why?
| | Thyroid Neoplasms | 1 | 2009 | 116 | 0.280 |
Why?
| | Skin, Artificial | 1 | 2007 | 11 | 0.270 |
Why?
| | MicroRNAs | 2 | 2023 | 388 | 0.270 |
Why?
| | Hearing Loss, Unilateral | 3 | 2013 | 12 | 0.270 |
Why?
| | Fasciitis, Necrotizing | 1 | 2006 | 7 | 0.260 |
Why?
| | Atlanto-Axial Joint | 1 | 2006 | 7 | 0.260 |
Why?
| | Pediatrics | 3 | 2025 | 294 | 0.260 |
Why?
| | Emphysema | 1 | 2006 | 15 | 0.260 |
Why?
| | Diet | 1 | 2010 | 588 | 0.260 |
Why?
| | Arytenoid Cartilage | 2 | 2020 | 4 | 0.250 |
Why?
| | Photography | 2 | 2020 | 31 | 0.250 |
Why?
| | Recurrence | 6 | 2016 | 682 | 0.250 |
Why?
| | Disease Management | 3 | 2019 | 186 | 0.250 |
Why?
| | Tinnitus | 1 | 2006 | 60 | 0.250 |
Why?
| | Bone Conduction | 3 | 2017 | 26 | 0.250 |
Why?
| | Transcranial Magnetic Stimulation | 1 | 2006 | 72 | 0.240 |
Why?
| | Esophagus | 3 | 2020 | 83 | 0.240 |
Why?
| | Esophagoscopy | 2 | 2020 | 27 | 0.240 |
Why?
| | Reoperation | 6 | 2014 | 466 | 0.240 |
Why?
| | Genetic Predisposition to Disease | 4 | 2019 | 528 | 0.240 |
Why?
| | Radiography | 2 | 2018 | 474 | 0.240 |
Why?
| | Branchial Region | 1 | 2024 | 4 | 0.230 |
Why?
| | Myringoplasty | 1 | 2024 | 6 | 0.220 |
Why?
| | Gene Expression Regulation | 2 | 2020 | 1004 | 0.220 |
Why?
| | Epithelial-Mesenchymal Transition | 1 | 2024 | 57 | 0.220 |
Why?
| | Middle Aged | 16 | 2024 | 13094 | 0.220 |
Why?
| | Tympanic Membrane Perforation | 1 | 2024 | 20 | 0.220 |
Why?
| | Fellowships and Scholarships | 2 | 2016 | 125 | 0.210 |
Why?
| | Cross-Sectional Studies | 3 | 2022 | 1682 | 0.210 |
Why?
| | Animals | 12 | 2019 | 13465 | 0.210 |
Why?
| | Patient Selection | 2 | 2019 | 266 | 0.210 |
Why?
| | Single-Blind Method | 2 | 2020 | 116 | 0.210 |
Why?
| | Diagnostic Imaging | 2 | 2017 | 173 | 0.210 |
Why?
| | Internship and Residency | 2 | 2020 | 441 | 0.200 |
Why?
| | Cohort Studies | 5 | 2020 | 1551 | 0.200 |
Why?
| | Antigens, Nuclear | 2 | 2013 | 24 | 0.200 |
Why?
| | Treatment Failure | 2 | 2016 | 122 | 0.200 |
Why?
| | Magnetic Resonance Imaging | 5 | 2015 | 1536 | 0.200 |
Why?
| | Transplantation, Heterologous | 2 | 2013 | 78 | 0.200 |
Why?
| | Prognosis | 4 | 2018 | 2116 | 0.200 |
Why?
| | Mandible | 1 | 2023 | 25 | 0.200 |
Why?
| | Esthetics, Dental | 1 | 2022 | 6 | 0.200 |
Why?
| | Tracheal Stenosis | 2 | 2015 | 13 | 0.200 |
Why?
| | Vocal Cords | 1 | 2022 | 9 | 0.190 |
Why?
| | Mice, Nude | 2 | 2013 | 235 | 0.190 |
Why?
| | Patient Readmission | 1 | 2024 | 246 | 0.190 |
Why?
| | Transforming Growth Factor beta1 | 1 | 2022 | 62 | 0.190 |
Why?
| | Length of Stay | 2 | 2024 | 674 | 0.190 |
Why?
| | Disease Progression | 3 | 2011 | 872 | 0.190 |
Why?
| | Immunoenzyme Techniques | 2 | 2013 | 136 | 0.190 |
Why?
| | Nevus, Blue | 1 | 2022 | 11 | 0.190 |
Why?
| | Respiratory Sounds | 2 | 2019 | 50 | 0.190 |
Why?
| | Gastrointestinal Neoplasms | 1 | 2022 | 42 | 0.180 |
Why?
| | Databases, Factual | 1 | 2025 | 715 | 0.180 |
Why?
| | Case-Control Studies | 2 | 2017 | 1201 | 0.180 |
Why?
| | Rats, Sprague-Dawley | 5 | 2009 | 1544 | 0.180 |
Why?
| | Dose-Response Relationship, Drug | 4 | 2013 | 1372 | 0.170 |
Why?
| | Operating Rooms | 1 | 2021 | 27 | 0.170 |
Why?
| | Nausea | 1 | 2021 | 46 | 0.170 |
Why?
| | Efficiency, Organizational | 1 | 2021 | 41 | 0.170 |
Why?
| | Air Microbiology | 1 | 2020 | 12 | 0.170 |
Why?
| | Mouth Mucosa | 1 | 2020 | 23 | 0.170 |
Why?
| | Thrombelastography | 1 | 2020 | 27 | 0.170 |
Why?
| | DiGeorge Syndrome | 1 | 2020 | 19 | 0.170 |
Why?
| | Reference Values | 2 | 2011 | 313 | 0.170 |
Why?
| | Hemostasis | 1 | 2020 | 61 | 0.170 |
Why?
| | LIM Domain Proteins | 1 | 2020 | 8 | 0.170 |
Why?
| | Retinal Dehydrogenase | 1 | 2020 | 10 | 0.170 |
Why?
| | Myosin Type I | 1 | 2020 | 5 | 0.170 |
Why?
| | Antiporters | 1 | 2020 | 19 | 0.170 |
Why?
| | Receptors, Notch | 1 | 2020 | 28 | 0.160 |
Why?
| | Diagnosis, Differential | 3 | 2019 | 1045 | 0.160 |
Why?
| | Hearing Loss, Conductive | 2 | 2011 | 55 | 0.160 |
Why?
| | Mastoid | 3 | 2009 | 51 | 0.160 |
Why?
| | Parasomnias | 1 | 2019 | 4 | 0.160 |
Why?
| | Cytoskeletal Proteins | 1 | 2020 | 48 | 0.160 |
Why?
| | Microsurgery | 2 | 2011 | 30 | 0.160 |
Why?
| | Pain, Postoperative | 1 | 2021 | 169 | 0.160 |
Why?
| | Analysis of Variance | 2 | 2014 | 558 | 0.160 |
Why?
| | Tertiary Care Centers | 1 | 2020 | 83 | 0.160 |
Why?
| | Surgical Wound Infection | 1 | 2020 | 117 | 0.160 |
Why?
| | Physician Assistants | 1 | 2019 | 19 | 0.160 |
Why?
| | Basic Helix-Loop-Helix Transcription Factors | 1 | 2020 | 44 | 0.160 |
Why?
| | Tetralogy of Fallot | 1 | 2020 | 84 | 0.160 |
Why?
| | Mitochondrial Proteins | 1 | 2020 | 90 | 0.160 |
Why?
| | Endothelium, Vascular | 1 | 2021 | 258 | 0.160 |
Why?
| | Neovascularization, Pathologic | 1 | 2020 | 158 | 0.160 |
Why?
| | Elastic Tissue | 1 | 2019 | 10 | 0.160 |
Why?
| | Ambulatory Care | 1 | 2021 | 239 | 0.160 |
Why?
| | Professional Role | 1 | 2019 | 78 | 0.150 |
Why?
| | Microcirculation | 1 | 2019 | 63 | 0.150 |
Why?
| | Age Factors | 4 | 2013 | 1134 | 0.150 |
Why?
| | Nurse Practitioners | 1 | 2019 | 44 | 0.150 |
Why?
| | Continuous Positive Airway Pressure | 1 | 2019 | 65 | 0.150 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2020 | 200 | 0.150 |
Why?
| | Tryptases | 1 | 2018 | 4 | 0.150 |
Why?
| | Rats | 5 | 2009 | 3180 | 0.150 |
Why?
| | Sirolimus | 1 | 2019 | 72 | 0.150 |
Why?
| | Dexamethasone | 1 | 2021 | 439 | 0.150 |
Why?
| | Mice | 4 | 2017 | 5944 | 0.150 |
Why?
| | p120 GTPase Activating Protein | 1 | 2018 | 1 | 0.150 |
Why?
| | Fibrosis | 1 | 2019 | 197 | 0.150 |
Why?
| | Heart Defects, Congenital | 1 | 2024 | 619 | 0.150 |
Why?
| | Port-Wine Stain | 1 | 2018 | 14 | 0.150 |
Why?
| | Estrogen Receptor beta | 1 | 2018 | 54 | 0.150 |
Why?
| | Constriction, Pathologic | 1 | 2018 | 91 | 0.150 |
Why?
| | Cryosurgery | 1 | 2018 | 36 | 0.140 |
Why?
| | Airway Extubation | 1 | 2018 | 30 | 0.140 |
Why?
| | Random Allocation | 2 | 2009 | 285 | 0.140 |
Why?
| | Estrogen Receptor alpha | 1 | 2018 | 85 | 0.140 |
Why?
| | Protein Transport | 1 | 2018 | 183 | 0.140 |
Why?
| | Ultrasonography, Doppler | 1 | 2018 | 41 | 0.140 |
Why?
| | Optical Phenomena | 1 | 2017 | 5 | 0.140 |
Why?
| | Nanomedicine | 1 | 2017 | 15 | 0.140 |
Why?
| | Palatine Tonsil | 1 | 2017 | 11 | 0.140 |
Why?
| | Neovascularization, Physiologic | 2 | 2009 | 87 | 0.140 |
Why?
| | Faculty, Medical | 2 | 2019 | 91 | 0.140 |
Why?
| | beta-Thromboglobulin | 1 | 2017 | 1 | 0.140 |
Why?
| | Aggressive Periodontitis | 1 | 2017 | 1 | 0.140 |
Why?
| | Platelet Factor 4 | 1 | 2017 | 2 | 0.140 |
Why?
| | Cadaver | 1 | 2017 | 95 | 0.140 |
Why?
| | Chemokine CXCL5 | 1 | 2017 | 7 | 0.140 |
Why?
| | Constipation | 1 | 2017 | 37 | 0.140 |
Why?
| | Pressure | 1 | 2017 | 103 | 0.140 |
Why?
| | Angiotensinogen | 1 | 2017 | 12 | 0.140 |
Why?
| | Pathology, Surgical | 1 | 2017 | 23 | 0.130 |
Why?
| | Antibiotics, Antineoplastic | 1 | 2018 | 79 | 0.130 |
Why?
| | Intubation, Intratracheal | 1 | 2018 | 117 | 0.130 |
Why?
| | Peptidyl-Dipeptidase A | 1 | 2017 | 27 | 0.130 |
Why?
| | Transcriptome | 1 | 2020 | 367 | 0.130 |
Why?
| | Receptor, Angiotensin, Type 1 | 1 | 2017 | 56 | 0.130 |
Why?
| | Diarrhea | 1 | 2017 | 95 | 0.130 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2018 | 179 | 0.130 |
Why?
| | Middle Ear Ventilation | 1 | 2016 | 16 | 0.130 |
Why?
| | Aged | 10 | 2022 | 10197 | 0.130 |
Why?
| | Otitis Media with Effusion | 1 | 2016 | 16 | 0.130 |
Why?
| | Child Behavior Disorders | 1 | 2017 | 77 | 0.130 |
Why?
| | Apoptosis | 3 | 2020 | 1122 | 0.130 |
Why?
| | Child Behavior | 1 | 2017 | 108 | 0.130 |
Why?
| | Mitochondria | 1 | 2020 | 425 | 0.130 |
Why?
| | Food Hypersensitivity | 1 | 2017 | 100 | 0.130 |
Why?
| | Serum | 1 | 2016 | 32 | 0.120 |
Why?
| | Tobacco Smoke Pollution | 1 | 2016 | 55 | 0.120 |
Why?
| | Drug Administration Schedule | 2 | 2013 | 375 | 0.120 |
Why?
| | Hearing Loss | 1 | 2017 | 96 | 0.120 |
Why?
| | Nasopharyngeal Diseases | 1 | 2015 | 2 | 0.120 |
Why?
| | Nasal Obstruction | 1 | 2015 | 11 | 0.120 |
Why?
| | Anticoagulants | 1 | 2018 | 279 | 0.120 |
Why?
| | Urinary Bladder | 1 | 2015 | 101 | 0.110 |
Why?
| | Inflammation | 1 | 2019 | 644 | 0.110 |
Why?
| | Bandages, Hydrocolloid | 1 | 2014 | 4 | 0.110 |
Why?
| | Gels | 1 | 2014 | 22 | 0.110 |
Why?
| | Endoscopy, Digestive System | 1 | 2014 | 53 | 0.110 |
Why?
| | North America | 1 | 2014 | 77 | 0.110 |
Why?
| | Biopsy, Needle | 1 | 2015 | 182 | 0.110 |
Why?
| | Early Diagnosis | 1 | 2014 | 87 | 0.110 |
Why?
| | Foreign Bodies | 2 | 2020 | 66 | 0.110 |
Why?
| | Sickness Impact Profile | 1 | 2014 | 28 | 0.110 |
Why?
| | Term Birth | 1 | 2013 | 17 | 0.110 |
Why?
| | Administration, Oral | 2 | 2018 | 455 | 0.110 |
Why?
| | Vascular Endothelial Growth Factor Receptor-2 | 1 | 2013 | 38 | 0.110 |
Why?
| | Hospitals, University | 1 | 2013 | 75 | 0.100 |
Why?
| | Polysomnography | 1 | 2013 | 72 | 0.100 |
Why?
| | Angiography | 3 | 2007 | 116 | 0.100 |
Why?
| | Actins | 1 | 2013 | 117 | 0.100 |
Why?
| | Otologic Surgical Procedures | 2 | 2009 | 37 | 0.100 |
Why?
| | Pregnancy | 1 | 2019 | 2670 | 0.100 |
Why?
| | Bronchoscopy | 2 | 2010 | 75 | 0.100 |
Why?
| | Algorithms | 1 | 2016 | 669 | 0.090 |
Why?
| | Incidence | 2 | 2013 | 1076 | 0.090 |
Why?
| | Gene Transfer Techniques | 2 | 2002 | 44 | 0.090 |
Why?
| | Bone Neoplasms | 1 | 1994 | 185 | 0.090 |
Why?
| | Antiviral Agents | 1 | 2013 | 177 | 0.090 |
Why?
| | Hearing Loss, Sensorineural | 1 | 2013 | 79 | 0.090 |
Why?
| | Lymphocele | 1 | 2011 | 7 | 0.090 |
Why?
| | Tissue Survival | 1 | 2011 | 10 | 0.090 |
Why?
| | Statistics, Nonparametric | 2 | 2014 | 196 | 0.090 |
Why?
| | Antibodies, Monoclonal, Murine-Derived | 1 | 2011 | 47 | 0.090 |
Why?
| | Tissue Culture Techniques | 1 | 2011 | 43 | 0.090 |
Why?
| | Ultrasonography, Interventional | 1 | 2012 | 139 | 0.090 |
Why?
| | Education, Medical, Graduate | 1 | 2014 | 217 | 0.090 |
Why?
| | Internet | 1 | 2014 | 261 | 0.090 |
Why?
| | Arkansas | 3 | 2016 | 2029 | 0.090 |
Why?
| | Lymphocytosis | 1 | 2011 | 4 | 0.090 |
Why?
| | Laryngeal Edema | 1 | 2011 | 5 | 0.090 |
Why?
| | Liver | 1 | 2017 | 1155 | 0.090 |
Why?
| | Genetic Therapy | 2 | 2002 | 124 | 0.090 |
Why?
| | Brain | 1 | 2019 | 1321 | 0.090 |
Why?
| | Hypertrophy | 1 | 2011 | 54 | 0.090 |
Why?
| | Infant, Premature | 1 | 2013 | 327 | 0.090 |
Why?
| | Nutritional Support | 1 | 2010 | 34 | 0.090 |
Why?
| | Fetus | 3 | 2021 | 197 | 0.080 |
Why?
| | Lip Neoplasms | 1 | 2010 | 3 | 0.080 |
Why?
| | Burns | 2 | 2002 | 164 | 0.080 |
Why?
| | Auditory Threshold | 1 | 2010 | 54 | 0.080 |
Why?
| | Tracheal Diseases | 1 | 2010 | 13 | 0.080 |
Why?
| | Hospitals, Teaching | 1 | 2010 | 53 | 0.080 |
Why?
| | Thyroglossal Cyst | 1 | 2009 | 4 | 0.080 |
Why?
| | Tongue Diseases | 1 | 2009 | 6 | 0.080 |
Why?
| | Medical Records | 1 | 2010 | 87 | 0.080 |
Why?
| | United States | 5 | 2025 | 5225 | 0.080 |
Why?
| | Vincristine | 1 | 2009 | 88 | 0.080 |
Why?
| | Calcitonin | 1 | 2009 | 30 | 0.080 |
Why?
| | Blood Flow Velocity | 2 | 2020 | 95 | 0.080 |
Why?
| | Sensory Thresholds | 1 | 2009 | 15 | 0.080 |
Why?
| | Granulation Tissue | 1 | 2009 | 10 | 0.080 |
Why?
| | Antineoplastic Agents, Phytogenic | 1 | 2009 | 70 | 0.080 |
Why?
| | Rhinitis | 1 | 2009 | 28 | 0.080 |
Why?
| | Lymphotoxin-alpha | 1 | 2009 | 7 | 0.080 |
Why?
| | Tympanic Membrane | 1 | 2009 | 37 | 0.080 |
Why?
| | Societies, Medical | 2 | 2025 | 202 | 0.080 |
Why?
| | Neoplasm Invasiveness | 1 | 2010 | 278 | 0.080 |
Why?
| | Mucous Membrane | 1 | 2009 | 31 | 0.080 |
Why?
| | Physical Examination | 1 | 2009 | 99 | 0.080 |
Why?
| | Sinusitis | 1 | 2009 | 42 | 0.080 |
Why?
| | Turner Syndrome | 1 | 2008 | 15 | 0.080 |
Why?
| | Thyroidectomy | 1 | 2009 | 61 | 0.080 |
Why?
| | Biopsy, Fine-Needle | 1 | 2009 | 104 | 0.080 |
Why?
| | Infusions, Intravenous | 1 | 2009 | 221 | 0.070 |
Why?
| | Transplantation, Homologous | 1 | 2009 | 151 | 0.070 |
Why?
| | X-Ray Intensifying Screens | 1 | 2008 | 3 | 0.070 |
Why?
| | Ear Diseases | 1 | 2008 | 28 | 0.070 |
Why?
| | Burns, Electric | 1 | 2008 | 2 | 0.070 |
Why?
| | Vasodilation | 2 | 2000 | 101 | 0.070 |
Why?
| | Chi-Square Distribution | 1 | 2009 | 295 | 0.070 |
Why?
| | Shock, Septic | 1 | 2009 | 70 | 0.070 |
Why?
| | Fires | 1 | 2008 | 15 | 0.070 |
Why?
| | Suction | 1 | 2008 | 23 | 0.070 |
Why?
| | Gastrointestinal Hemorrhage | 2 | 2022 | 91 | 0.070 |
Why?
| | Cerebral Angiography | 1 | 2008 | 91 | 0.070 |
Why?
| | Intracranial Aneurysm | 1 | 2008 | 45 | 0.070 |
Why?
| | Sleep Apnea Syndromes | 1 | 2008 | 32 | 0.070 |
Why?
| | Photomicrography | 1 | 2007 | 7 | 0.070 |
Why?
| | Factor VII | 1 | 2007 | 3 | 0.070 |
Why?
| | Hospitals, Pediatric | 2 | 2019 | 243 | 0.070 |
Why?
| | Neoplasm Staging | 1 | 2010 | 767 | 0.070 |
Why?
| | Mouth Floor | 1 | 2007 | 5 | 0.070 |
Why?
| | Postoperative Care | 1 | 2008 | 103 | 0.070 |
Why?
| | Polyvinyl Alcohol | 1 | 2007 | 10 | 0.070 |
Why?
| | Biocompatible Materials | 1 | 2007 | 65 | 0.070 |
Why?
| | Collateral Circulation | 1 | 2007 | 38 | 0.070 |
Why?
| | Intraoperative Complications | 1 | 2008 | 113 | 0.070 |
Why?
| | Auditory Cortex | 1 | 2006 | 19 | 0.070 |
Why?
| | Patient Satisfaction | 1 | 2008 | 284 | 0.060 |
Why?
| | Therapy, Computer-Assisted | 1 | 2006 | 31 | 0.060 |
Why?
| | Thalamus | 1 | 2006 | 35 | 0.060 |
Why?
| | Arousal | 1 | 2006 | 101 | 0.060 |
Why?
| | Swine | 1 | 2007 | 427 | 0.060 |
Why?
| | Psychomotor Performance | 1 | 2006 | 126 | 0.060 |
Why?
| | Phenotype | 2 | 2019 | 800 | 0.060 |
Why?
| | Reaction Time | 1 | 2006 | 208 | 0.060 |
Why?
| | Attention | 1 | 2006 | 167 | 0.060 |
Why?
| | Preoperative Care | 1 | 2007 | 174 | 0.060 |
Why?
| | Radiopharmaceuticals | 1 | 2006 | 205 | 0.060 |
Why?
| | Fluorodeoxyglucose F18 | 1 | 2006 | 188 | 0.060 |
Why?
| | Fibroblast Growth Factors | 2 | 2002 | 49 | 0.060 |
Why?
| | Chronic Disease | 3 | 2016 | 588 | 0.060 |
Why?
| | DNA, Complementary | 2 | 2002 | 132 | 0.060 |
Why?
| | Advisory Committees | 1 | 2025 | 71 | 0.060 |
Why?
| | Emergency Service, Hospital | 1 | 2009 | 524 | 0.060 |
Why?
| | Positron-Emission Tomography | 1 | 2006 | 303 | 0.060 |
Why?
| | Craniofacial Abnormalities | 1 | 2024 | 27 | 0.060 |
Why?
| | Human Umbilical Vein Endothelial Cells | 1 | 2024 | 102 | 0.050 |
Why?
| | Mice, Inbred C57BL | 1 | 2009 | 1897 | 0.050 |
Why?
| | Otitis Media | 2 | 2016 | 30 | 0.050 |
Why?
| | Anti-Bacterial Agents | 1 | 2009 | 802 | 0.050 |
Why?
| | Mutation | 2 | 2019 | 1342 | 0.050 |
Why?
| | Growth Differentiation Factor 2 | 1 | 2022 | 6 | 0.050 |
Why?
| | Apoptosis Regulatory Proteins | 1 | 2023 | 87 | 0.050 |
Why?
| | Sheep | 2 | 2000 | 98 | 0.050 |
Why?
| | Transforming Growth Factor beta | 1 | 2022 | 139 | 0.050 |
Why?
| | Registries | 1 | 2025 | 629 | 0.050 |
Why?
| | alpha-Fetoproteins | 1 | 2001 | 12 | 0.040 |
Why?
| | Esophagoscopes | 1 | 2020 | 1 | 0.040 |
Why?
| | Blood Coagulation Tests | 1 | 2020 | 18 | 0.040 |
Why?
| | Blood Coagulation | 1 | 2020 | 62 | 0.040 |
Why?
| | Gastrostomy | 1 | 2020 | 58 | 0.040 |
Why?
| | Ligands | 1 | 2020 | 207 | 0.040 |
Why?
| | Exhalation | 1 | 2019 | 21 | 0.040 |
Why?
| | Embryonic Development | 1 | 2019 | 18 | 0.040 |
Why?
| | Risk | 1 | 2020 | 313 | 0.040 |
Why?
| | Hepatitis C | 1 | 2001 | 80 | 0.040 |
Why?
| | Genetic Loci | 1 | 2019 | 49 | 0.040 |
Why?
| | Disease Susceptibility | 1 | 2019 | 96 | 0.040 |
Why?
| | Income | 1 | 2019 | 103 | 0.040 |
Why?
| | Angiogenesis Inhibitors | 1 | 2020 | 184 | 0.040 |
Why?
| | Genetic Association Studies | 1 | 2019 | 123 | 0.040 |
Why?
| | Syndrome | 1 | 2019 | 252 | 0.040 |
Why?
| | Alcohol Drinking | 1 | 2001 | 236 | 0.040 |
Why?
| | Hemorrhage | 1 | 2020 | 224 | 0.040 |
Why?
| | Double-Blind Method | 1 | 2020 | 718 | 0.040 |
Why?
| | Gene Expression | 1 | 2021 | 623 | 0.040 |
Why?
| | Pulmonary Circulation | 1 | 1998 | 28 | 0.040 |
Why?
| | Comparative Genomic Hybridization | 1 | 2018 | 39 | 0.040 |
Why?
| | Fibrin Fibrinogen Degradation Products | 1 | 2018 | 9 | 0.040 |
Why?
| | Carcinoma, Hepatocellular | 1 | 2001 | 201 | 0.040 |
Why?
| | Liver Cirrhosis | 1 | 2001 | 243 | 0.040 |
Why?
| | Fibrinogen | 1 | 2018 | 34 | 0.040 |
Why?
| | Equipment Design | 2 | 2010 | 290 | 0.040 |
Why?
| | Lymphatic System | 1 | 2018 | 13 | 0.040 |
Why?
| | Peptic Ulcer Hemorrhage | 1 | 1997 | 4 | 0.030 |
Why?
| | Tertiary Healthcare | 1 | 2017 | 15 | 0.030 |
Why?
| | Tissue Adhesives | 1 | 1997 | 15 | 0.030 |
Why?
| | DNA-Binding Proteins | 1 | 2020 | 426 | 0.030 |
Why?
| | Linkage Disequilibrium | 1 | 2017 | 41 | 0.030 |
Why?
| | Catheterization | 2 | 1996 | 97 | 0.030 |
Why?
| | Polyethylene Glycols | 1 | 1997 | 91 | 0.030 |
Why?
| | Quantitative Trait Loci | 1 | 2017 | 51 | 0.030 |
Why?
| | Liver Neoplasms | 1 | 2001 | 333 | 0.030 |
Why?
| | Haplotypes | 1 | 2017 | 95 | 0.030 |
Why?
| | Transcription Factors | 1 | 2020 | 566 | 0.030 |
Why?
| | Cost-Benefit Analysis | 1 | 2017 | 269 | 0.030 |
Why?
| | Genome-Wide Association Study | 1 | 2017 | 184 | 0.030 |
Why?
| | Leg | 1 | 1996 | 121 | 0.030 |
Why?
| | Genotype | 1 | 2017 | 572 | 0.030 |
Why?
| | Triage | 1 | 2016 | 66 | 0.030 |
Why?
| | Arterial Occlusive Diseases | 1 | 1996 | 82 | 0.030 |
Why?
| | Pain | 1 | 2018 | 359 | 0.030 |
Why?
| | Thrombolytic Therapy | 1 | 1996 | 113 | 0.030 |
Why?
| | Fibrinolytic Agents | 1 | 1996 | 132 | 0.030 |
Why?
| | Multivariate Analysis | 1 | 2016 | 602 | 0.030 |
Why?
| | Odds Ratio | 1 | 2016 | 568 | 0.030 |
Why?
| | Quality-Adjusted Life Years | 1 | 2015 | 67 | 0.030 |
Why?
| | Software | 1 | 2017 | 281 | 0.030 |
Why?
| | Patient-Centered Care | 1 | 2016 | 140 | 0.030 |
Why?
| | Portasystemic Shunt, Surgical | 1 | 1994 | 6 | 0.030 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2017 | 507 | 0.030 |
Why?
| | Esophageal and Gastric Varices | 1 | 1994 | 17 | 0.030 |
Why?
| | Job Application | 1 | 2014 | 12 | 0.030 |
Why?
| | Aged, 80 and over | 3 | 2015 | 3417 | 0.030 |
Why?
| | Hypertension, Portal | 1 | 1994 | 23 | 0.030 |
Why?
| | Personnel Selection | 1 | 2014 | 25 | 0.030 |
Why?
| | Logistic Models | 1 | 2016 | 934 | 0.030 |
Why?
| | Personal Satisfaction | 1 | 2014 | 75 | 0.030 |
Why?
| | Temporal Bone | 1 | 2013 | 34 | 0.030 |
Why?
| | Carcinoma, Renal Cell | 1 | 1994 | 112 | 0.030 |
Why?
| | Patient Care Team | 1 | 2015 | 273 | 0.030 |
Why?
| | Practice Guidelines as Topic | 1 | 2016 | 496 | 0.020 |
Why?
| | Patient Admission | 1 | 2013 | 80 | 0.020 |
Why?
| | Kidney Neoplasms | 1 | 1994 | 182 | 0.020 |
Why?
| | Fibroblast Growth Factor 7 | 2 | 2002 | 5 | 0.020 |
Why?
| | Oximetry | 1 | 2013 | 66 | 0.020 |
Why?
| | Program Evaluation | 1 | 2014 | 351 | 0.020 |
Why?
| | Liposomes | 2 | 2002 | 55 | 0.020 |
Why?
| | Liver Transplantation | 1 | 1994 | 166 | 0.020 |
Why?
| | Insulin-Like Growth Factor I | 2 | 2002 | 142 | 0.020 |
Why?
| | Decision Making | 1 | 2014 | 282 | 0.020 |
Why?
| | Transfection | 2 | 2002 | 370 | 0.020 |
Why?
| | Cell Division | 2 | 2002 | 290 | 0.020 |
Why?
| | Electrocardiography | 1 | 2013 | 281 | 0.020 |
Why?
| | Referral and Consultation | 1 | 2013 | 292 | 0.020 |
Why?
| | Stents | 1 | 1994 | 373 | 0.020 |
Why?
| | Survival Rate | 2 | 2008 | 953 | 0.020 |
Why?
| | Blood Pressure | 1 | 2013 | 536 | 0.020 |
Why?
| | Lymphoid Tissue | 1 | 2010 | 21 | 0.020 |
Why?
| | Blood Glucose | 1 | 2013 | 473 | 0.020 |
Why?
| | Suture Anchors | 1 | 2010 | 11 | 0.020 |
Why?
| | Fiber Optic Technology | 1 | 2010 | 14 | 0.020 |
Why?
| | Safety | 1 | 2010 | 80 | 0.020 |
Why?
| | Prolapse | 1 | 2009 | 6 | 0.020 |
Why?
| | Skin Diseases, Infectious | 1 | 1968 | 8 | 0.020 |
Why?
| | Eczema | 1 | 1968 | 12 | 0.020 |
Why?
| | Ear, Middle | 1 | 2008 | 19 | 0.020 |
Why?
| | Demography | 1 | 2009 | 92 | 0.020 |
Why?
| | Electric Power Supplies | 1 | 2008 | 1 | 0.020 |
Why?
| | Equipment Failure Analysis | 1 | 2008 | 44 | 0.020 |
Why?
| | Acute Disease | 1 | 2009 | 387 | 0.020 |
Why?
| | Drainage | 1 | 2008 | 87 | 0.020 |
Why?
| | Factor VIIa | 1 | 2007 | 8 | 0.020 |
Why?
| | Postoperative Hemorrhage | 1 | 2007 | 55 | 0.020 |
Why?
| | Brain Damage, Chronic | 1 | 1986 | 15 | 0.020 |
Why?
| | Angiomatosis | 1 | 1965 | 7 | 0.020 |
Why?
| | Recombinant Proteins | 1 | 2007 | 495 | 0.020 |
Why?
| | Anemia | 1 | 1965 | 75 | 0.010 |
Why?
| | Sex Factors | 2 | 2001 | 731 | 0.010 |
Why?
| | Skin Physiological Phenomena | 1 | 2002 | 16 | 0.010 |
Why?
| | Epidermis | 1 | 2002 | 33 | 0.010 |
Why?
| | Regeneration | 1 | 2002 | 80 | 0.010 |
Why?
| | Germany | 1 | 2001 | 24 | 0.010 |
Why?
| | Epidemiologic Studies | 1 | 2001 | 23 | 0.010 |
Why?
| | Age of Onset | 1 | 2001 | 111 | 0.010 |
Why?
| | Endothelin-1 | 1 | 2000 | 35 | 0.010 |
Why?
| | Nitric Oxide Synthase | 1 | 2000 | 64 | 0.010 |
Why?
| | Sensitivity and Specificity | 1 | 2001 | 883 | 0.010 |
Why?
| | Hemodynamics | 1 | 2000 | 265 | 0.010 |
Why?
| | Regional Blood Flow | 1 | 1998 | 110 | 0.010 |
Why?
| | Blood Vessel Prosthesis | 1 | 1996 | 85 | 0.010 |
Why?
| | Lung | 1 | 1998 | 501 | 0.010 |
Why?
| | Hepatic Veins | 1 | 1994 | 5 | 0.010 |
Why?
| | Portacaval Shunt, Surgical | 1 | 1994 | 11 | 0.010 |
Why?
| | Portal Vein | 1 | 1994 | 27 | 0.010 |
Why?
| | Cause of Death | 1 | 1994 | 162 | 0.010 |
Why?
| | Germany, East | 1 | 1968 | 4 | 0.000 |
Why?
| | Dermatitis, Seborrheic | 1 | 1968 | 4 | 0.000 |
Why?
| | Dermatomycoses | 1 | 1968 | 15 | 0.000 |
Why?
| | Seasons | 1 | 1968 | 92 | 0.000 |
Why?
| | Dermatitis, Atopic | 1 | 1968 | 40 | 0.000 |
Why?
| | Personality Development | 1 | 1986 | 5 | 0.000 |
Why?
| | Education, Special | 1 | 1986 | 9 | 0.000 |
Why?
| | Social Adjustment | 1 | 1986 | 27 | 0.000 |
Why?
| | Psychological Tests | 1 | 1986 | 50 | 0.000 |
Why?
| | Intelligence | 1 | 1986 | 53 | 0.000 |
Why?
| | Intellectual Disability | 1 | 1986 | 128 | 0.000 |
Why?
| | Skin Diseases | 1 | 1965 | 116 | 0.000 |
Why?
| | Gastrointestinal Diseases | 1 | 1965 | 126 | 0.000 |
Why?
| | Brain Injuries | 1 | 1986 | 159 | 0.000 |
Why?
| | Attention Deficit Disorder with Hyperactivity | 1 | 1986 | 179 | 0.000 |
Why?
|
|
Richter's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|